** Shares of Maryland-based vaccine maker Novavax NVAX.O fall 2.8% to $7.96
** Co says it received a notice on March 7 terminating with immediate effect a purchase agreement with Canada due to missed regulatory approval deadlines for its COVID-19 vaccine
** Co entered into the purchase agreement with Canada in January 2021
** Under the terms of the agreement, $28 million in advanced purchase payments previously received by the company are now refundable to the customer within 30 days of notice
** Up to last close, NVAX had risen 50.% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments